Tests dapagliflozin to limit heart damage after a heart attack
Tests dapagliflozin against placebo in adults with ST elevation heart attack.
Plain-language title generated from the registry record
Registry title: Dapagliflozin in STEMI
Key facts
- Where
- Ottawa, CanadaSee the site
- Phase
- Phase 3
Where in Canada
- University of Ottawa Heart InstituteOttawa, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ottawa Heart Institute Research Corporation
- Trial code
- NCT06174753
- Record updated
- 20 February 2026
- Original description
The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI.Read full original descriptionShow less
The University of Ottawa Dapagliflozin in STEMI Randomized Clinical Trial
The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI.
Eligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo.
Cardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.
Inclusion: Patients referred for PPCI meeting the following criteria are eligible for the study:; Ischemic chest discomfort of ≥30 minutes duration, and; Onset of chest pain ≤12 hours prior to entry into the study, and; One of the following High-Risk criteria on a standard 12 lead ECG:; Anterior STEMI with ST-segment elevation ≥2mm (0.2 mV) in each of at least 2 contiguous precordial leads (V1-V6) b. Extensive non-anterior STEMI defined as ST-segment elevation of >1mm in two or more contiguous non-anterior leads accompanied by i. 8 or more leads with > 1 mm ST elevation or depression, or both; OR ii. Sum of ST- segment elevation >20mm.
Exclusion: Therapy with SGLT2i within last 8 weeks; Chronic symptomatic HF with prior hospitalization for HF within the last year; Known history of prior MI; Previous randomization in the present study; Participation in a study with another investigational device or drug < four weeks; Type 1 diabetes mellitus; Any non-CV condition with a life expectancy of less than one year; Known severe hepatic impairment (Cirrhosis); Known severe valvular heart disease; Severe renal impairment (eGFR < 30 mL/min1.73m2 (based on prior or baseline blood work); Age < 18 years; Any contraindication to undergo CMR imaging; Killip 4 (Cardiogenic shock on presentation); Pregnancy; Nursing mother; Unwilling to use appropriate forms of contraception, as applicable; hospitalization; Inability to provide informed consent; Confirmed ketoacidosis at time of admission; Need for CABG within 90 days based on the results of the initial coronary angiogram; False positive STEMI (based on the results of the coronary angiogram).